{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:01:20Z","timestamp":1792036880073,"version":"4.4.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,8]]},"DOI":"10.7759\/cureus.98761","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T02:21:08Z","timestamp":1765246868000},"source":"Crossref","is-referenced-by-count":3,"title":["Rapid and Successful Treatment of Generalized Granuloma Annulare With Deucravacitinib"],"prefix":"10.7759","author":[{"given":"Michael J","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabelle P","family":"Avenido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Ames","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00636-1","article-title":"Granuloma annulare: an updated review of epidemiology, pathogenesis, and treatment options","volume":"23","author":"Joshi TP","year":"2022","unstructured":"Joshi TP, Duvic M. Granuloma annulare: an updated review of epidemiology, pathogenesis, and treatment options. Am J Clin Dermatol. 2022, 23:37-50. 10.1007\/s40257-021-00636-1","journal-title":"Am J Clin Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.054","article-title":"Granuloma annulare: clinical and histologic variants, epidemiology, and genetics","volume":"75","author":"Piette EW","year":"2016","unstructured":"Piette EW, Rosenbach M. Granuloma annulare: clinical and histologic variants, epidemiology, and genetics. J Am Acad Dermatol. 2016, 75:457-65. 10.1016\/j.jaad.2015.03.054","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.1847","article-title":"Incidence and prevalence of granuloma annulare in the United States","volume":"157","author":"Barbieri JS","year":"2021","unstructured":"Barbieri JS, Rodriguez O, Rosenbach M, Margolis D. Incidence and prevalence of granuloma annulare in the United States. JAMA Dermatol. 2021, 157:824-30. 10.1001\/jamadermatol.2021.1847","journal-title":"JAMA Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.098","article-title":"Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare","volume":"82","author":"Damsky W","year":"2020","unstructured":"Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2020, 82:612-21. 10.1016\/j.jaad.2019.05.098","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.1805","article-title":"Association of granuloma annulare with type 2 diabetes, hyperlipidemia, autoimmune disorders, and hematologic malignant neoplasms","volume":"157","author":"Barbieri JS","year":"2021","unstructured":"Barbieri JS, Rosenbach M, Rodriguez O, Margolis DJ. Association of granuloma annulare with type 2 diabetes, hyperlipidemia, autoimmune disorders, and hematologic malignant neoplasms. JAMA Dermatol. 2021, 157:817-23. 10.1001\/jamadermatol.2021.1805","journal-title":"JAMA Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.012","article-title":"Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib","volume":"147","author":"Wang A","year":"2021","unstructured":"Wang A, Rahman NT, McGeary MK, et al.. Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib. J Allergy Clin Immunol. 2021, 147:1795-809. 10.1016\/j.jaci.2020.10.012","journal-title":"J Allergy Clin Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.05.030","article-title":"Ruxolitinib cream for the treatment of granuloma annulare","volume":"50","author":"Piontkowski AJ","year":"2024","unstructured":"Piontkowski AJ, Wei N, Mumtaz A, Gulati N. Ruxolitinib cream for the treatment of granuloma annulare. JAAD Case Rep. 2024, 50:62-4. 10.1016\/j.jdcr.2024.05.030","journal-title":"JAAD Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13875","article-title":"Treatment of granuloma annulare with tofacitinib","volume":"63","author":"Bosch-Amate X","year":"2022","unstructured":"Bosch-Amate X, Serra-Garc\u00eda L, Alamon-Reig F, Marti-Marti I, Gil-Lianes J, Giavedoni P, Mascar\u00f3 JM Jr. Treatment of granuloma annulare with tofacitinib. Australas J Dermatol. 2022, 63:400-3. 10.1111\/ajd.13875","journal-title":"Australas J Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4331\/wjbc.v13.i1.1","article-title":"Current understanding of the role of tyrosine kinase 2 signaling in immune responses","volume":"13","author":"Muromoto R","year":"2022","unstructured":"Muromoto R, Oritani K, Matsuda T. Current understanding of the role of tyrosine kinase 2 signaling in immune responses. World J Biol Chem. 2022, 13:1-14. 10.4331\/wjbc.v13.i1.1","journal-title":"World J Biol Chem"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220094","article-title":"Impaired IL-23-dependent induction of IFN-\u03b3 underlies mycobacterial disease in patients with inherited TYK2 deficiency","volume":"219","author":"Ogishi M","year":"2022","unstructured":"Ogishi M, Arias AA, Yang R, et al.. Impaired IL-23-dependent induction of IFN-\u03b3 underlies mycobacterial disease in patients with inherited TYK2 deficiency. J Exp Med. 2022, 219:10.1084\/jem.20220094","journal-title":"J Exp Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043391","article-title":"Tyk2 targeting in immune-mediated inflammatory diseases","volume":"24","author":"Rusi\u00f1ol L","year":"2023","unstructured":"Rusi\u00f1ol L, Puig L. Tyk2 targeting in immune-mediated inflammatory diseases. Int J Mol Sci. 2023, 24:10.3390\/ijms24043391","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2025.02.034","article-title":"Generalized granuloma annulare successfully treated with deucravacitinib (Sotyktu)","volume":"60","author":"Lapa T","year":"2025","unstructured":"Lapa T, Breslavets M. Generalized granuloma annulare successfully treated with deucravacitinib (Sotyktu). JAAD Case Rep. 2025, 60:79-82. 10.1016\/j.jdcr.2025.02.034","journal-title":"JAAD Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.4688","article-title":"Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3 years: an open-label extension of randomized clinical trials","volume":"161","author":"Armstrong AW","year":"2025","unstructured":"Armstrong AW, Lebwohl M, Warren RB, et al.. Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3 years: an open-label extension of randomized clinical trials. JAMA Dermatol. 2025, 161:56-66. 10.1001\/jamadermatol.2024.4688","journal-title":"JAMA Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/434080-rapid-and-successful-treatment-of-generalized-granuloma-annulare-with-deucravacitinib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T02:21:09Z","timestamp":1765246869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/434080-rapid-and-successful-treatment-of-generalized-granuloma-annulare-with-deucravacitinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.98761","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,8]]}}}